The impact of GLP-1 analogues on cardiovascular risk

Kołakowska, Klaudia; Miłkowska, Urszula; Piech, Gabriela Maria; Lis, Igor

doi:10.2478/bgbl-2024-0030

Abstract

The population of patients with type 2 diabetes is characterized by higher cardiovascular risk than the general population. It has been shown that glycemic control declines the incidence of serious cardiovascular events. The aim of this literature review is to elucidate the effect of GLP-1 analogues on cardiovascular risk factors. Interestingly, recent scientific reports suggest that GLP-1 analogues reduce cardiovascular risk also in a mechanism unrelated to the hypoglycemic effect of the drug, but also apart from weight loss. The direct cardioprotective effect of GLP-1 analogues is associated with the expression of GLP-1 receptors in heart and vascular smooth muscle cells. Moreover, a protective effect of GLP-1 analogues has been found in cell interactions between endothelium, immune system cells, thrombocytes in preventing the formation of atherosclerotic plaques. GLP-1 receptors are also expressed in epicardial fat. Epicardial fat modulation after treatment with GLP-1 analogues may decline the risk of serious adverse cardiovascular events. Clinical cardiovascular outcome trials (CVOT) were conducted to elucidate the influence of GLP-1 analogues on the cardiovascular system in patients with type 2 diabetes. Five CVOT studies of GLP-1 analogues have shown that therapy with these drugs reduces cardiovascular risk in type 2 diabetes patients. However, two studies (ELIXA and EXSCEL) demonstrated a neutral effect of lixisenatide and exenatide on cardiovascular risk in type 2 diabetes patients. Moreover, it was also shown that semaglutide declines cardiovascular risk also in obese individuals without diabetes. Therefore, international guidelines recommend the implementing liraglutide, semaglutide and dulaglutide in the therapy regime to reduce the risk of cardiovascular events in patients at higher cardiovascular risk.

References

Smith NK, Hackett TA, Galli A, Flynn CR (2019) GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int 128:94–105. https://doi.org/10.1016/j.neuint.2019.04.010.
Search in Google Scholar Back to article
Drucker DJ (2018) Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab 27:740–756. https://doi.org/10.1016/j.cmet.2018.03.001.
Search in Google Scholar Back to article
Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102. https://doi.org/10.1016/j.molmet.2020.101102.
Search in Google Scholar Back to article
Wong ND, Sattar N (2023) Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol 20:685–695. https://doi.org/10.1038/s41569–023–00877-z.
Search in Google Scholar Back to article
Ussher JR, Drucker DJ (2023) Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20:463–474. https://doi.org/10.1038/s41569–023–00849–3.
Search in Google Scholar Back to article
Schnell O, Barnard-Kelly K, Battelino T, et al (2024) CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol 23:104. https://doi.org/10.1186/s12933–024–02180–8.
Search in Google Scholar Back to article
Teo KK, Rafiq T (2021) Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. Can J Cardiol 37:733–743. https://doi.org/10.1016/j.cjca.2021.02.009.
Search in Google Scholar Back to article
Wang L, Lei J, Wang R, Li K (2023) Non-Traditional Risk Factors as Contributors to Cardiovascular Disease. Rev Cardiovasc Med 24:134. https://doi.org/10.31083/j.rcm2405134.
Search in Google Scholar Back to article
SCORE2 working group and ESC Cardiovascular risk collaboration (2021) SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 42:2439–2454. https://doi.org/10.1093/eurheartj/ehab309.
Search in Google Scholar Back to article
SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration (2023) SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 44:2544–2556. https://doi.org/10.1093/eurheartj/ehad260.
Search in Google Scholar Back to article
Sattar N, Lee MMY, Kristensen SL, et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9:653–662. https://doi.org/10.1016/S2213–8587(21)00203–5.
Search in Google Scholar Back to article
Bertoccini L, Baroni MG (2021) GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. Adv Exp Med Biol 1307:193–212. https://doi.org/10.1007/5584_2020_494.
Search in Google Scholar Back to article
Tahrani AA, Morton J (2022) Benefits of weight loss of 10% or more in patients with overweight or obesity: A review. Obesity (Silver Spring) 30:802–840. https://doi.org/10.1002/oby.23371.
Search in Google Scholar Back to article
Nauck MA, Quast DR (2021) Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne) 12:645566. https://doi.org/10.3389/fendo.2021.645566.
Search in Google Scholar Back to article
Iacobellis G, Ribaudo MC, Assael F, et al (2003) Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 88:5163–8. https://doi.org/10.1210/jc.2003–030698.
Search in Google Scholar Back to article
Iacobellis G, Lonn E, Lamy A, et al (2011) Epicardial fat thickness and coronary artery disease correlate independently of obesity. Int J Cardiol 146:452–4. https://doi.org/10.1016/j.ijcard.2010.10.117.
Search in Google Scholar Back to article
Iacobellis G, Camarena V, Sant DW, Wang G (2017) Human Epicardial Fat Expresses Glucagon-Like Peptide 1 and 2 Receptors Genes. Horm Metab Res 49:625–630. https://doi.org/10.1055/s-0043–109563.
Search in Google Scholar Back to article
Iacobellis G, Baroni MG (2022) Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J Endocrinol Invest 45:489–495. https://doi.org/10.1007/s40618–021–01687–1.
Search in Google Scholar Back to article
Schnell O, Battelino T, Bergenstal R, et al (2023) CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol 22:59. https://doi.org/10.1186/s12933–023–01788–6.
Search in Google Scholar Back to article
Marso SP, Daniels GH, Brown-Frandsen K, et al (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375:311–22. https://doi.org/10.1056/NEJMoa1603827.
Search in Google Scholar Back to article
Pfeffer MA, Claggett B, Diaz R, et al (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373:2247–57. https://doi.org/10.1056/NEJMoa1509225.
Search in Google Scholar Back to article
Marso SP, Bain SC, Consoli A, et al (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375:1834–1844. https://doi.org/10.1056/NEJMoa1607141.
Search in Google Scholar Back to article
McGuire DK, Busui RP, Deanfield J, et al (2023) Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab 25:1932–1941. https://doi.org/10.1111/dom.15058.
Search in Google Scholar Back to article
Holman RR, Bethel MA, Mentz RJ, et al (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 377:1228–1239. https://doi.org/10.1056/NEJMoa1612917.
Search in Google Scholar Back to article
Gerstein HC, Colhoun HM, Dagenais GR, et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130. https://doi.org/10.1016/S0140–6736(19)31149–3.
Search in Google Scholar Back to article
Hernandez AF, Green JB, Janmohamed S, et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double--blind, randomised placebo-controlled trial. Lancet 392:1519–1529. https://doi.org/10.1016/S0140–6736(18)32261-X.
Search in Google Scholar Back to article
Kristensen SL, Rørth R, Jhund PS, et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776–785. https://doi.org/10.1016/S2213–8587(19)30249–9.
Search in Google Scholar Back to article
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389:2221–2232. https://doi.org/10.1056/NEJMoa2307563.
Search in Google Scholar Back to article

The impact of GLP-1 analogues on cardiovascular risk

Abstract

Paradigm

My account